ACTIV-2: A Platform Trial for the Evaluation of Novel Therapeutics for the Treatment of Early COVID-19 in Outpatients

By sjmartinez • August 31, 2023

Currier JS, Moser C, Eron JJ, Chew KW, Smith DM, Javan AC, Wohl DA, Daar ES, Hughes MD; ACTIV-2/A5401 Study Team. ACTIV-2: A Platform Trial for the Evaluation of Novel Therapeutics for the Treatment of Early COVID-19 in Outpatients. J Infect Dis. 2023 Aug 31;228(Supplement_2):S77-S82. doi: 10.1093/infdis/jiad246. PMID: 37650231; PMCID: PMC10469341.

Tags: ACTIV-2, Clinical Trial, covid-19, Harbor UCLA, Infectious Diseases, Monoclonal antibodies, Publications

Efficacy of an oral lipid nanocrystal formulation of amphotericin B (MAT2203) in the neutropenic mouse model of pulmonary mucormycosis

Gu Y, Gebremariam T, Alkhazraji S, Youssef E, El-Gamal S, Matkovits T, Cobb J, Mannino R, Ibrahim AS. Efficacy of an oral lipid nanocrystal formulation[...]

A Leaky False Pouch: Left Ventricle Pseudoaneurysm with Active Hemopericardium Detected on Cardiac Computed Tomography Angiography

Barforoshi S, Shekar C, Yu Z, Liu E, Manubolu V, Budoff MJ, Roy SK. A Leaky False Pouch: Left Ventricle Pseudoaneurysm with Active Hemopericardium Detected[...]

Comparing Cardiovascular Events Across Home Dialysis Modalities: Adjusting the Unadjustable?

Nadeau-Fredette AC, Shen JI, Perl J. Comparing Cardiovascular Events Across Home Dialysis Modalities: Adjusting the Unadjustable? Kidney360. 2024 Apr 1;5(4):489-491. doi: 10.34067/KID.0000000000000397. PMID: 38662536.